July 8, 2025 01:15 AM EDTUpdated 05:42 AM

Novartis maps launch of malaria drug for newborns after Swiss approval

Ayisha Sharma

News Reporter

Novartis has secured approval in Switzerland for its malaria treatment for small babies and infants, with plans to launch the first-of-its-kind drug on a not …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Novartis maps launch of malaria drug for newborns after Swiss approval

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Trump's tax cut law expands orphan drug exclusions, could upend 340B program

Clinician groups sue RFK Jr. and HHS over Covid-19 vaccine recommendation changes

FDA chief calls for 'meaningful' reduction of animal testing for new drugs

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene

Apogee reports Phase 2 win for eczema drug that could challenge Dupixent and Ebglyss

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases

No­var­tis maps launch of malar­ia drug for new­borns af­ter Swiss ap­proval

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Trump's tax cut law ex­pands or­phan drug ex­clu­sions, could up­end 340B pro­gram

Clin­i­cian groups sue RFK Jr. and HHS over Covid-19 vac­cine rec­om­men­da­tion changes

FDA chief calls for 'mean­ing­ful' re­duc­tion of an­i­mal test­ing for new drugs

De­spite de­lay, KalVista wins FDA ap­proval af­ter Makary's short-lived at­tempt to in­ter­vene

Apogee re­ports Phase 2 win for eczema drug that could chal­lenge Dupix­ent and Ebglyss

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

Novartis maps launch of malaria drug for newborns after Swiss approval

Trump's tax cut law expands orphan drug exclusions, could upend 340B program

Clinician groups sue RFK Jr. and HHS over Covid-19 vaccine recommendation changes

FDA chief calls for 'meaningful' reduction of animal testing for new drugs

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene

Apogee reports Phase 2 win for eczema drug that could challenge Dupixent and Ebglyss

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases